UK-based clinical-stage drug discovery and development company Summit Therapeutics has reported positive Phase I clinical trial results of ezutromid to treat Duchenne muscular dystrophy (DMD) and Clostridium difficile infection.

Ezutromid, referred to as F6, is an orally administered utrophin modulator believed to slow down the progression of DMD regardless of the dystrophin gene mutation.

The second part of the Phase I clinical trial has been designed to evaluate the pharmacokinetics and safety of three fixed doses of ezutromid in patients suffering from DMD, aged between five and nine years.

Results of the study displayed an increase in plasma levels within patients compared to the current clinical formulation of ezutromid referred to as F3.

"Following these encouraging Phase I data, we plan to incorporate the F6 formulation of ezutromid into our ongoing Phase II trial, PhaseOut DMD."

Summit chief medical officer Dr Ralf Rosskamp said: “Following this encouraging Phase I data, we plan to incorporate the F6 formulation of ezutromid into our ongoing Phase II trial, PhaseOut DMD.

“This will allow us to directly compare the safety and efficacy of the F6 and F3 formulations of ezutromid, and help determine which to use in future clinical trials.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“Utrophin modulation focuses on maintaining expression of utrophin protein to protect muscle health and function and we believe these two formulations of ezutromid are capable of achieving this.

"It is therefore appropriate to now outline our clinical pathway to seek marketing approval of ezutromid.”

Ezutromid was tolerable across all dosages.

Summit is now planning to apply the new formulation of F6 into its ongoing, PhaseOut DMD, Phase II proof-of-concept trial.